Cosmetic composition

Abstract

The present invention provides a cosmetic composition comprising isostearic acid, isostearyl alcohol, glycerin, and a lipopeptide compound having a cyclic structure or a salt thereof, which has excellent penetration-promoting effect, and has good transparency and long-term transparency stability in a specific composition.

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of cosmetics, and in particular, the present application relates to a cosmetic composition which can form a microemulsion having a good transparent appearance and excellent stability, and which has a good penetration promoting effect on a bioactive substance. BACKGROUND

[0002] A cosmetic composition for external use on the skin not only imparts a good appearance (whitening, blemish coverage, or artistic modification, etc.), but also inhibits skin defects, increases skin nutrition, and improves or relieves skin damage caused by surface wounds or skin aging.

[0003] Therefore, in a cosmetic composition for external use on the skin, it is generally desirable to incorporate a functional component acceptable to the human body, typically by the addition of a bioactive substance, to achieve a promoting and nurturing effect on skin health.

[0004] Further, as a method for achieving the above-mentioned purpose, it has been proposed or attempted to use a mechanism similar to a transdermal drug delivery system, by contacting a skin external agent containing a functional component with the skin, to purposefully supply the functional component to the target site. At this time, not only is it required that the functional component have good dispersibility, but it is also desirable that it have good skin permeability.

[0005] In addition, it is also known that, as a cosmetic composition for external use on the skin, a system of a pure aqueous phase, a pure oil phase, and a water-oil two-phase system is commonly used and used. In particular, in the water-oil two-phase system, in order to maintain the necessary stability, a surfactant is a necessary component, which utilizes the affinity of the aqueous phase or the oil phase to make the dispersed phase particles in the emulsion have good emulsion stability.

[0006] Therefore, as a viable attempt, the use of a surfactant as an auxiliary component for improving the skin permeability or absorption of a functional component (especially a bioactive component), a pharmaceutical ingredient has been studied. For example, in Reference Document 1, sucrose fatty acid ester as a nonionic surfactant is used as an auxiliary component for promoting the transdermal absorption of a drug, and it has excellent biodegradability, low skin irritation, and excellent promotion of the transdermal absorption of a molecular drug compound.

[0007] Further, as a surfactant having an emulsifying function, the pursuit of better emulsion stability, low toxicity, and environmental friendliness in a cosmetic composition for external use on the skin is also increasingly evident. Therefore, surfactants of biological origin are also increasingly valued.

[0008] For the biological source of surfactant, can be roughly divided into lipopeptide, sugar ester, phospholipid and other neutral fat and other kinds. Among them, reference 2 discloses a green biological surfactant with strong emulsifying function-sodium subtilisin lipopeptide, which can be obtained by biological fermentation, and it has been verified that it has excellent dispersing and emulsifying stability, and it also has lower irritation to human body than other commonly used surfactants (SDS, etc.).

[0009] Further, for the promotion of the transdermal delivery of the lipopeptide with cyclic structure to the biologically active substances, reference 3 also proves that the results show that in the Franz cell diffusion cell method test, every 1% by weight of the lipopeptide compound or its salt makes the skin permeability of the physiologically active ingredient increase by more than twice compared with the case without adding the lipopeptide compound or its salt.

[0010] In addition, reference 4 describes a cosmetic composition using a lipopeptide compound or its salt with a cyclic structure. The composition can have high transparency by the cooperation of specific components with the lipopeptide compound, even if an oil component is additionally used in the composition to form a clear emulsion (especially an oil-in-water emulsion), and can also impart a clear and refreshing external appearance to the product, while improving the promotion of skin penetration of the lipopeptide compound to the biologically active components.

[0011] On the other hand, for skin external use type cosmetic composition, in addition to the pursuit of comfort and functionality during use, in modern commerce, more and more attention is paid to the beauty and individualization of the appearance of the product. It is generally believed that the appearance of cosmetics that can bring people a refreshing and crystal feeling can cater to the preferences of consumers in many cases.

[0012] Although the above-mentioned research has been carried out in the prior art field, for the skin external use type cosmetic composition, there is still room for improvement in its functionality, external appearance and other properties.

[0013] Reference:

[0014] Reference 1: JP2003-238446A

[0015] Reference 2: "Biological surfactant with cyclic peptide structure", Zou Qingqing et al., "New technology and new product", February 2016

[0016] Reference 3: JP5906194B2

[0017] Reference 4: CN202211723366.2 SUMMARY

[0018] Problem to be solved by the invention

[0019] As described above, although the use of a lipopeptide compound having a cyclic structure, which has strong emulsifying properties, is environmentally friendly and has low human body irritation, has been studied to some extent, the following problems have also been found in the production practice of cosmetic compositions:

[0020] When the above-described lipopeptide compound having a cyclic structure or a salt thereof is used as an emulsifier, it is generally used in combination with a certain component of a moisturizing agent, such as glycerin or the like (it is presumed that the moisturizing agent can be used as a solvent for the lipopeptide compound), as in Reference Literature 3, and when the above-described combination is made, in a multi-component cosmetic composition, it does not seem to exhibit the desired effect of sufficiently promoting the skin permeability of a bioactive ingredient.

[0021] In addition, as disclosed in Reference Literature 2, see the attached Figure 6 (Reference Literature 2 Figure 2 ) prepared an emulsion system containing various surfactants, and although the emulsion system using a lipopeptide compound having a cyclic structure or a salt thereof (KANEKA surfactin) exhibited high emulsifying properties and emulsion stability. But also because of its high emulsifying properties, it has a distinct white, opaque appearance when forming an emulsion system, which is not conducive to the production of skin-external cosmetic products in terms of giving a clear and sparkling appearance.

[0022] In Patent Literature 4, by using each component, a good penetration-promoting effect was obtained, and even in the case of forming an emulsion, a cosmetic composition having high transparency could be provided, which could further impart a clear and sparkling external appearance to the product, and also improve the promotion of skin permeability of a bioactive ingredient by a lipopeptide compound. However, there is still room for improvement in terms of long-term transparency maintenance under a specific composition.

[0023] Therefore, in view of the above-mentioned problems in the art in the use of a lipopeptide compound having a cyclic structure or a salt thereof to prepare a skin-external cosmetic composition, the purpose of the present invention is to provide a microemulsion that not only has a good penetration-promoting effect on active substances and system transparency, but also can maintain such transparency for a long time under a specific combination of components.

[0024] Solution to the problem

[0025] Through the in-depth research of the inventor, it is found that the above technical problems can be solved by implementing the following technical solutions:

[0026] [1] A cosmetic composition, wherein the composition comprises the following components:

[0027] (A) isostearic acid,

[0028] (B) isostearyl alcohol, and

[0029] (C) other components, based on the total weight of the (C) other components, the (C) other components including:

[0030] (C1) a lipopeptide compound having a cyclic structure or a salt thereof 0.294 wt. %,

[0031] (C2) squalane 0.176 wt. %,

[0032] (C3) glycerin 10.666 wt. %,

[0033] (C4) 1,3-butanediol 0.147 wt. %,

[0034] (C5) a preservative 0.499 wt. %, and

[0035] (C6) water 88.218 wt. %;

[0036] wherein the content of the components (A), (B), (C) is in a range enclosed by the following coordinates of an equilateral triangle coordinate system in a ternary diagram of components (A), (B), and (C) connected by straight lines:

[0037] (0.08, 0.13, 99.79), (0.06, 0.20, 99.75), (0.06, 0.29, 99.65), (0.10, 0.29, 99.61), (0.15, 0.20, 99.66), (0.18, 0.13, 99.69).

[0038] [2] The cosmetic composition according to [1], wherein the (C1) is a metal salt of a subtilin lipopeptide.

[0039] [3] The cosmetic composition according to [1], wherein the (C5) is phenoxyethanol.

[0040] [4] A cosmetic composition, wherein the composition includes the following components:

[0041] (a) glycerin

[0042] (b) 1,3-butanediol

[0043] (c) other components, based on the total weight of the (c) other components, the (c) other components including:

[0044] (c1) a lipopeptide compound having a cyclic structure or a salt thereof 0.3282 wt. %,

[0045] (c2) squalane 0.1969 wt. %,

[0046] (c3) isostearyl alcohol 0.1477 wt. %,

[0047] (c4) isostearic acid 0.1477 wt. %,

[0048] (c5) preservative 0.5579 wt. % and

[0049] (c6) water 98.6216 %;

[0050] wherein the content of the components (a), (b), (c) is in the range enclosed by the straight lines connecting the following coordinates in the equilateral triangle coordinate system of the ternary diagram of components (a), (b) and (c):

[0051] (9.85 0.07, 90.07), (9.86, 0.04, 90.11), (9.95, 0.07, 89.97), (9.96, 0.04, 90.01), (10.05 0.15, 89.81), (10.06, 0.04, 89.91), (10.24, 0.15, 89.61), (10.26, 0.02, 89.72), (10.47, 1.71, 87.82), (10.65, 0.01, 89.34).

[0052] [5] The cosmetic composition according to [4], wherein the (c1) is a metal salt of a subtilisin lipopeptide.

[0053] [6] The cosmetic composition according to [4], wherein the (c5) is phenoxyethanol.

[0054] [7] The cosmetic composition according to any one of [1] to [6], characterized in that the composition is an oil-in-water emulsified composition.

[0055] Effects of the Invention

[0056] Through the implementation of the above technical solution, the present application can achieve the following technical effects:

[0057] 1) The cosmetic composition provided by the present application can form a microemulsion with excellent transparency and stability, which can provide a user with a refreshing and non-greasy visual and use experience, and even when an additional oil component (to form a clear emulsion) is added, it can maintain a high transparent state;

[0058] 2) The cosmetic composition provided by the present invention, by mixing specific components in specific proportions, allows the lipopeptide compound having a cyclic structure or its salt (A) to retain its good surface activity and antibacterial properties, and the resulting composition can also form a microemulsion with excellent transparency and stable transparency.

[0059] 3) The cosmetic composition provided by the present invention can have a further improved effect of promoting the transdermal absorption of functional components, especially bioactive components. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 is the NMR spectrum of Surfactin used in the examples;

[0061] Figure 2 A and 2B are the infrared spectrum and structure of Surfactin used in the examples, respectively;

[0062] Figure 3A This is a photo of the appearance of the sample in Example 1;

[0063] Figure 3B The particle size and PDI diagram of the sample in Example 1 were determined by dynamic light scattering;

[0064] Figure 3C is the pseudo-ternary phase diagram obtained in Example 1;

[0065] Figure 4A This is a photo of the appearance of the sample in Example 2;

[0066] Figure 4B and 4C This is a photo of the pH stability test in Example 2;

[0067] Figure 5A This is a photo of the appearance of the sample in Example 3;

[0068] Figure 5B The particle size and PDI diagram of the sample in Example 2 were determined by dynamic light scattering;

[0069] Figure 5C is the pseudo-ternary phase diagram obtained in Example 2;

[0070] Figure 6 Reference 2 Figure 2 . DETAILED DESCRIPTION

[0071] The following is a detailed description of the present invention. The following description of the technical features is based on representative embodiments and specific examples of the present invention, but the present invention is not limited to these embodiments and specific examples. It should be noted that:

[0072] In the present specification, a numerical range indicated using "numerical value A to numerical value B" means a range including the end point values A and B.

[0073] In the present specification, "substantially" or "essentially" means within 3%, preferably 2%, more preferably 1% of the standard deviation from a theoretical model or theoretical data, and the deviation here also includes systematic deviation.

[0074] In the present specification, the meaning of "may" includes both the meaning of performing a certain process and the meaning of not performing a certain process.

[0075] In the present specification, "ordinary temperature" or "room temperature" means an indoor temperature of 23±2°C.

[0076] In the present specification, "first raw material portion" and "second raw material portion" are merely names for distinguishing each other, and "first" and "second" do not mean an order-related meaning or concept.

[0077] In the present specification, "optional" or "optionally" means that the event or circumstance described next can or can not occur, and the description includes the case where the event occurs and the case where the event does not occur.

[0078] In the present specification, the reference to "some specific / preferred embodiments", "other specific / preferred embodiments", "embodiments", and the like means that the particular element (e.g., feature, structure, property, and / or characteristic) described in relation to the embodiment is included in at least one embodiment described herein, and can or can not be present in other embodiments. In addition, it should be understood that the described elements can be combined in any suitable manner in various embodiments.

[0079] <First Aspect>

[0080] The first aspect of the present application provides a composition, the composition including the following components:

[0081] (A) isostearic acid,

[0082] (B) isostearyl alcohol, and

[0083] (C) other components, the other components including:

[0084] (C1) a lipopeptide compound having a cyclic structure or a salt thereof 0.294 wt. %,

[0085] (C2) squalane 0.176 wt. %,

[0086] (C3) glycerin 10.666 wt. %

[0087] (C4) 1,3-butanediol 0.147 wt. %,

[0088] (C5) preservative 0.499 wt. % and

[0089] (C6) water 88.218 wt. %;

[0090] wherein the weight ratio of the components (A), (B), (C) is within the range enclosed by the following coordinates of the equilateral triangle coordinate system in the ternary diagram of components (A), (B) and (C) connected by straight lines:

[0091] (0.08, 0.13, 99.79), (0.06, 0.20, 99.75), (0.06, 0.29, 99.65), (0.10, 0.29, 99.61), (0.15, 0.20, 99.66), (0.18, 0.13, 99.69).

[0092] The composition of the present application is described in detail below.

[0093] Triplot

[0094] In the composition of the present application, the content of components (A), (B), (C) is within the range enclosed by the following coordinates of the equilateral triangle coordinate system in the ternary diagram of components (A), (B) and (C) connected by straight lines:

[0095] (0.08, 0.13, 99.79), (0.06, 0.20, 99.75), (0.06, 0.29, 99.65), (0.10, 0.29, 99.61), (0.15, 0.20, 99.66), (0.18, 0.13, 99.69).

[0096] In the present specification, the "ternary diagram of components (A), (B) and (C)" is an equilateral triangle whose three sides are the coordinates of the content proportions of components (A), (B) and (C) with respect to the entire composition. The point in the ternary diagram is expressed using coordinates (x, y, z), wherein x, y and z respectively represent the numerical values of the mass percent content of components (A), (B) and (C) (the percent sign is omitted for the sake of easy writing, for example, when x is 1, it means that the content of component (A) in the composition is 1 mass %). Parallel lines are drawn from the point (x, y, z) in the ternary diagram to the three sides, and the coordinates at the intersection points of the parallel lines and the respective sides are x%, y% and z%.

[0097] In the present specification, the "range surrounded by points connected in a straight line" given for each point means a set of component contents represented by all points within the closed figure formed by connecting the points in the order described, adjacent two points being connected in a straight line, and the first and last points (i.e., the first point and the last point) being connected in a straight line.

[0098] The present application obtains a composition which can form a microemulsion having excellent transparency and stability by allowing the contents of components (A), (B), (C) to be within the range surrounded by points connected in a straight line given in the ternary diagram.

[0099] The following describes each component of the composition of the present application in detail.

[0100] Component (A)

[0101] In the composition of the present application, component (A) is isostearic acid. The content of component (A) is 0.06 to 0.18% by weight based on the total weight of the composition.

[0102] Component (B)

[0103] In the composition of the present application, component (B) is isostearyl alcohol. The content of component (B) is 0.13 to 0.29% by weight based on the total weight of the composition.

[0104] Component (C)

[0105] In the composition of the present application, component (C) includes components (C1) to (C6) in the above-mentioned specific amounts.

[0106] In a preferred embodiment, component (C) consists of components (C1) to (C6).

[0107] The following describes components (C1) to (C6) in component (C) respectively.

[0108] Component (C1)

[0109] In the composition of the present application, component (C1) is a biosurfactant having surface activity, and specifically, it is a lipopeptide surfactant having a cyclic structure.

[0110] The specific structure of the above-mentioned lipopeptide surfactant is not particularly limited in the present application, and the specific structure of these substances or salts thereof is represented by the substance of formula (1) disclosed in JP 5906194 B2 cited as prior art in the present application.

[0111] Further, the salt of the cyclic lipopeptide compound can be various metal salts, and in the present application, a combination of one or more of alkali metal salts, alkaline earth metal salts, or ammonium salts is preferred, and more preferably, the salt is an alkali metal salt, particularly a sodium salt.

[0112] For the component (A) of the present application, it can be obtained by microbial fermentation technology in principle. In some preferred embodiments of the present application, it can be produced by microbial fermentation technology of Bacillus Subtilis, and then an anionic, cyclic lipopeptide surfactant component having extremely high water solubility can be obtained, which can be represented by the following structural formula (1), but the length of the alkyl chain and the position of the branched chain are not limited to the structural formula (1), and can include a structure in which one amino acid is replaced by another amino acid:

[0113]

[0114] The structure of formula (1) is a cyclic peptide hydrophilic group composed of seven amino acids, which is connected with a β-hydroxy fatty acid. Due to the unique cyclic peptide structure, when micelles are formed in water, hydrogen bonds can be formed between molecules, so that it has stronger binding capacity than other surfactants, because it can start to form aggregates with very few molecules. Therefore, according to the relevant reports, the critical micelle concentration (CMC) of the above structure is only 0.0003% (mass fraction), which is one of the surfactants with the lowest CMC, and it shows extremely strong emulsifying property.

[0115] For the above cyclic lipopeptide compound or its salt, one or more of their mixtures can be obtained by the above-mentioned biological fermentation method, or can be obtained by market purchase (KANEKA Surfactin).

[0116] In preferred embodiments, the component (C1) in the composition of the present application is KANEKA Surfactin, which is a highly effective biological surfactant of microbial origin produced by Bacillus subtilis strain. Unless otherwise specified, "KANEKA Surfactin" in the present specification refers to a substance having the structure shown in formula (1).

[0117] Component (C2)

[0118] In the composition of the present application, the component (C2) is squalane, which is used as an oil component, so that the composition of the present application can exist in the form of an emulsion. As described above, by the cooperation of the specific components of the present application, even when the composition exists in the form of an emulsion, it can have a transparent appearance and excellent stability.

[0119] Component (C3)

[0120] In the composition of the present application, component (C3) is glycerin. Generally, the glycerin component is used as a moisturizer or a solvent. In the present application, glycerin can be used as a co-surfactant, for dissolving the lipopeptide compound having a cyclic structure of (C1) or its salt or as a carrier thereof, and reducing the amount of the lipopeptide compound.

[0121] Therefore, component (C3) can be added to the composition alone or mixed with other components of the composition, or it can be mixed with component (C1) first and then mixed with other components to obtain the cosmetic composition of the present application.

[0122] Alternatively, a part of component (C3) can be mixed with at least a part of water as an aqueous phase, and the other part can be mixed with components (A), (B), (C1), (C2), (C4), and the other part of water as an oily phase, and then the oily phase can be mixed with the aqueous phase to obtain the composition of the present application.

[0123] Component (C4)

[0124] In the composition of the present application, component (C4) is 1,3-butanediol, which is used as a co-surfactant and can also partially function as a moisturizer / solvent. On the one hand, 1,3-butanediol as component (C4) can be added to the composition alone or mixed with other components of the composition, or it can be mixed with component (C1) at least in part first and then mixed with other components to obtain the cosmetic composition of the present application.

[0125] Component (C5)

[0126] In the composition of the present application, component (C5) is a preservative, and as for its specific type, the present application is not particularly limited, which can be any preservative known in the art that can be used in cosmetics, including but not limited to phenoxyethanol, tocopherol, etc., preferably phenoxyethanol.

[0127] Component (C5) can be added to the composition alone or mixed with other components of the composition, or it can be mixed with at least a part of water and then mixed with other components to obtain the composition of the present application.

[0128] Component (C6)

[0129] In the composition of the present application, component (C6) is water. Component (C6) can be added to the composition alone or mixed with other components of the composition.

[0130] Alternatively, a part of the component (C6) can be mixed with the components (C3) and (C5) as the water phase, and the other part can be mixed with the components (A), (B), (Cl), (C2), (C4) as the oil phase, and then the oil phase can be mixed with the water phase to obtain the composition of the present application.

[0131] Biologically active substance

[0132] As described above, as one function of the composition of the present application, if a bioactive substance is contained therein, the composition of the present application having a specific composition can improve the permeability of the lipopeptide compound to the human skin for the bioactive substance.

[0133] The bioactive substance that can be used in the present application is not particularly limited in principle, as long as the use thereof does not harm the transparency and stability of the composition of the present application.

[0134] Examples of the bioactive substance that can be used include one or more of an antioxidant component, a (bio)moisturizing component, an anti-aging component, a cell repair component, a cell nutrition component, a whitening promotion component, an antibacterial component, an anti-allergic component, a vitamin component, and the like.

[0135] Further, specific examples of the above-mentioned bioactive substances include: arbutin and its derivatives, L-ascorbic acid and its derivatives (e.g., ascorbyl phosphate), hydroquinone and its derivatives, glutathione and its derivatives, pantothenic acid and its derivatives, tranexamic acid and its derivatives, kojic acid and its derivatives, cysteine and its derivatives, ellagic acid and its derivatives, resorcinol derivatives, plant extracts such as chamomile extract and licorice extract, superoxide dismutase and its derivatives, mannitol and its derivatives, rutin and its derivatives, bilirubin and its derivatives, tryptophan and its derivatives, histidine and its derivatives, flavonoids such as quercetin and quercitrin, catechin and its derivatives, gallic acid and its derivatives, vitamin C and its derivatives (erythorbic acid and its derivatives), sesamin and its derivatives, alpha-lipoic acid and its derivatives, glycyrrhizin and its derivatives (glycyrrhizin such as dipotassium glycyrrhizinate and ammonium glycyrrhizinate), taurine and its derivatives, urea and its derivatives, glycerol and its derivatives, xylitol and its derivatives, erythritol and its derivatives, salicylic acid and its derivatives (e.g., salicylate and 4-methoxysalicylic acid), nicotine and its derivatives, nicotinic acid and its derivatives (e.g., nicotinate and nicotinamide), hydroxyproline and its derivatives, serine and its derivatives, glutamine acid and its derivatives (e.g., glutamic acid, pyroglutamic acid, pyroglutamic acid, L-theanine, etc.), trimethylglycine and its derivatives, arginine and its derivatives, alanine and its derivatives, adenosine and its derivatives, lysine and its derivatives, lumbrokinase and its derivatives, minoxidil and its derivatives, finasteride and its derivatives, flavanones, tannic acid and its derivatives, ferulic acid and its derivatives, fullerene and its derivatives, 1-hydroxymethyl-5,5-dimethylhydantoin and its derivatives, D-amino acids and their derivatives, oligosaccharides and their derivatives, D-glucosamine and its derivatives (e.g., chitin, chitosan, etc.), sodium chondroitin sulfate and its derivatives, sorbitol and its derivatives, trehalose and its derivatives, hyaluronic acid and its derivatives, maltitol and its derivatives, raffinose and its derivatives, alginic acid and its derivatives, caffeine and its derivatives, keratin hydrolysate and its derivatives, silk protein hydrolysate and its derivatives, azelaic acid and its derivatives, gamma-aminobutyric acid and its derivatives, allantoin and its derivatives, gamma-oryzanol and its derivatives, L-carnitine and its derivatives, beta-1,3-glucan and its derivatives, biotin and its derivatives, pyridoxine hydrochloride and its derivatives, propolis, and the like.

[0136] The amount of the above-mentioned bioactive substance is not particularly limited in principle, as long as the amount thereof does not impair the transparency and stability of the microemulsion formed by the composition of the present application. In some specific embodiments of the present application, the amount of the bioactive substance can be 0.01 to 1000 mass%, preferably 0.10 to 500 mass%, and more preferably 0.20 to 300 mass%, based on the mass of component (C1).

[0137] Further component

[0138] In addition to the above various components, other optional components can be included in the composition of the present application without affecting the technical effects of the present application.

[0139] These optional components include: other surfactants than the above components, humectants, powders, alcoholic solvents, water-soluble polymers, oil-soluble polymers, film formers, ultraviolet absorbers, preservatives, antibacterial agents, fragrances, salts, antioxidants, pH adjustors, chelating agents, cooling agents, anti-inflammatory agents, skin-beautifying ingredients, and the like.

[0140] The composition of the present application formed by the above various components can form a microemulsion having excellent transparency and stability even if it contains an oil component.

[0141] The present application accordingly provides a method for preparing the composition of the present application. In a specific embodiment, the method for preparing includes a step of mixing the components.

[0142] In a preferred embodiment, the method for preparing includes the following steps:

[0143] (i) preparing an aqueous phase: adding at least part of component (C3) and component (C5) to water to obtain an aqueous phase;

[0144] (ii) preparing an oil phase: mixing components (A), (B), (C1), (C2), at least part of (C3), (C4), and water to obtain an oil phase;

[0145] (iii) adding the above oil phase to the above aqueous phase, optionally with stirring.

[0146] <Second aspect>

[0147] The second aspect of the present application provides a composition including the following components:

[0148] (a) glycerin

[0149] (b) 1,3-butanediol

[0150] (c) other components, including, based on the total weight of the composition:

[0151] (c1) a lipopeptide compound having a cyclic structure or a salt thereof 0.3282 wt. %,

[0152] (c2) squalane 0.1969 wt. %,

[0153] (c3) isostearyl alcohol 0.1477 wt. %,

[0154] (c4) isostearic acid 0.1477 wt. %,

[0155] (c5) preservative 0.5579 wt. % and

[0156] (c6) water 98.6216 %;

[0157] wherein the content of the components (a), (b), (c) is within the range enclosed by the straight lines connecting the following coordinates in the ternary diagram of components (a), (b) and (c):

[0158] (9.85 0.07, 90.07), (9.86, 0.04, 90.11), (9.95, 0.07, 89.97), (9.96, 0.04, 90.01), (10.05 0.15, 89.81), (10.06, 0.04, 89.91), (10.24, 0.15, 89.61), (10.26, 0.02, 89.72), (10.47, 1.71, 87.82), (10.65, 0.01, 89.34).

[0159] The ternary diagram described in the first aspect and the related terms of meaning in the specification also apply to the second aspect.

[0160] The following describes the individual components of the composition of the second aspect of the present application in detail.

[0161] Component (a)

[0162] In the composition of the present application, component (a) is glycerin, and the content of component (a) is 9.85 to 10.65 mass % based on the total weight of the composition.

[0163] Component (a) can be added to the composition alone or mixed with other components of the composition, or a part of component (a) can be mixed with water and (c5) as an aqueous phase, and another part of component (a) can be mixed with components (b), (c1) to (c4) and water as an oil phase, and then the oil phase and the aqueous phase are mixed to obtain the composition of the present application.

[0164] Component (b)

[0165] In the composition of the present application, component (b) is 1,3-butanediol, and the content of component (b) is 0.01 to 1.71 mass % based on the total weight of the composition. Component (b) can be added to the composition alone or mixed with other components of the composition.

[0166] Component (c)

[0167] In the composition of the present application, component (c) includes components (cl) to (c6). In one embodiment, component (c) consists of components (cl) to (c6).

[0168] The content of component (c) is 87.82 to 90.11 mass% based on the total weight of the composition.

[0169] Component (c1)

[0170] In the composition of the present application, component (cl) is a lipopeptide compound having a cyclic structure or a salt thereof, and the content of component (cl) is 0.3283 mass% based on the total weight of component (c).

[0171] Further, the description of component (cl) in the composition of the first aspect of the present application above also applies to component (cl) of the composition of the second aspect.

[0172] Component (c2)

[0173] In the composition of the present application, component (c2) is squalane, and the content of component (c2) is 0.1969 mass% based on the total weight of component (c).

[0174] Component (c3)

[0175] In the composition of the present application, component (c3) is isostearyl alcohol, and the content of component (c3) is 0.1477 mass% based on the total weight of component (c).

[0176] Component (c4)

[0177] In the composition of the present application, component (c4) is isostearic acid, and the content of component (c4) is 0.1477 mass% based on the total weight of component (c).

[0178] Component (c5)

[0179] In the composition of the present application, component (c5) is a preservative, and the content of component (c5) is 0.5579 mass% based on the total weight of component (c).

[0180] Further, the description of component (c5) in the composition of the first aspect of the present application above also applies to component (c5) of the composition of the second aspect.

[0181] Component (c6)

[0182] In the composition of the present application, component (c6) is water, and the content of component (c6) is 98.6216 mass% based on the total weight of component (c).

[0183] Component (c6) can be added to the composition alone or mixed with other components of the composition. Alternatively, it can be first mixed with at least part of glycerol and then mixed with other components to obtain the composition of the present invention.

[0184] <Properties of the composition>

[0185] The composition of the present invention can form a microemulsion and has excellent transparency and stability.

[0186] In the microemulsion formed by the composition of the present invention, the particle size of the emulsion is 150 nm or less, preferably 100 nm or less.

[0187] The microemulsion formed by the composition of the present invention is stable within the range of pH 8 to 13.

[0188] In some specific embodiments, the microemulsion formed by the composition of the present invention can have an L value of 90 or more, preferably 95 or more, and more preferably 99 or more. And the L value after being stored at 50 °C for 3 days can also be greater than 80, preferably 85 or more. This shows the excellent transparency and stability of the transparency of the present invention. Because generally in the prior art, even the L value (immediately) of the microemulsion is usually only about 80 and does not exceed 90.

[0189] The L value is obtained by the following method:

[0190] The composition of the present invention is filled into a quartz glass cell (optical path length 10 mm) without dilution as a sample, and transmission measurement is carried out at 20 °C using an integrating sphere spectrophotometer (X.rite).

[0191] That is, light is irradiated onto the sample equally from various different angles through the integrating sphere, and the ratio (%) of the intensity of the transmitted light received in the normal direction of the sample surface to the intensity of the irradiated light is obtained and used as the L value.

[0192] Examples

[0193] Hereinafter, the present invention will be further illustrated by specific examples.

[0194] <Structural characterization of Surfactin>

[0195] Surfactin used in the following examples is the Surfactin raw material of KANEKA Corporation.

[0196] The Surfactin sample is tested for 1H NMR and 13C NMR, and the spectra are as Figure 1 shown. Figure 1 The spectra are consistent with the Surfactin structure reported in the existing literature.

[0197] Surfactin from different batches were characterized by Fourier infrared spectrum, as shown in Figure 2 A. As shown in Figure 2 A, there are absorption peaks of imino (-NH) at 3300-3500 cm -1 , -CH stretching vibration peaks at 2500-2700 cm -1 , and C=O peaks at 1600-1800 cm -1 , which are consistent with the structure of Surfactin shown in Figure 2 B. In addition, the comparison of the spectra of different batches shows that the infrared spectra of the two batches of products all appear vibration peaks at the same position, proving that the stability of Surfactin batches is good.

[0198] <Dynamic light scattering test>

[0199] Deionized water was filtered through a 0.2 μm filter to remove large particulate impurities, and the filtered deionized water was used to prepare the sample. 1 mL of sample was added to the sample cell, and the sample cell was placed into the nanoparticle size potential instrument after standing to remove air bubbles. After equilibration for two minutes, three consecutive DLS measurements were performed at 25°C.

[0200] Example 1

[0201] In this example, Surfactin was used as a surfactant to prepare a microemulsion by phase inversion. By changing the ratio of isostearyl alcohol and isostearic acid, a pseudo-ternary phase diagram was constructed to explore the suitable component ratio of the composition for forming a microemulsion.

[0202] The samples were prepared according to the following method and the amounts in Table 1.

[0203] (1) Aqueous phase: 1 g of glycerol was added to 9 g of deionized water to prepare a glycerol aqueous solution, and 0.051 g of phenoxyethanol was added as a preservative;

[0204] (2) Oil phase: 0.03 g of Surfactin was weighed into a beaker, and 0.09 g of glycerol, 0.018 g of squalane, 0.015 g of 1,3-butanediol, isostearic acid, isostearyl alcohol, 0.015 g of deionized water were added and stirred uniformly;

[0205] (3) The oil phase was added to the aqueous phase and stirred until uniform.

[0206] Table 1

[0207]

[0208] *Mass percentage based on the total mass of the oil phase excluding isostearic acid in the sample

[0209] The appearance of the prepared samples is as followsFigure 3A As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. Figure 3A As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed.

[0210] As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. Figure 3B As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. Figure 3B As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed.

[0211] As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. Figure 3C As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed.

[0212] As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed.

[0213] (0.08, 0.13, 99.79), (0.06, 0.20, 99.75), (0.06, 0.29, 99.65), (0.10, 0.29, 99.61), (0.15, 0.20, 99.66), (0.18, 0.13, 99.69). As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed.

[0214] As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed. As shown in Table 1, the samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed.

[0215] Example 2

[0216] In this example, the pH stability of the composition was studied.

[0217] The samples were prepared in the same manner as in Example 1, except that the amounts of the components were changed.

[0218] Table 2

[0219]

[0220] *Based on the mass percentage of the total oil phase in the sample excluding isostearic acid

[0221] The appearance of the configured sample is as follows Figure 4A As shown by Figure 4A It can be seen that all samples are clear and transparent microemulsions.

[0222] Add hydrochloric acid (HCl c = 0.1 mol / L) to the prepared sample and gradually adjust the pH to 1. The appearance of the sample at different pH values ​​is as follows: Figure 4B As shown ( Figure 4B The number marked on the beaker is the pH value of the corresponding sample). Figure 4B It can be seen that as the pH gradually decreases, the color of the sample deepens and gradually turns milky white. This shows that the stability of the composition of the present invention is poor under acidic conditions.

[0223] A potassium hydroxide aqueous solution (KOH c = 0.1 mol / L) was added to the prepared sample and the pH was gradually adjusted to 13. The appearance of the sample at different pH values ​​was as follows: Figure 4C As shown ( Figure 4C The number marked on the beaker is the pH value of the corresponding sample). Figure 4C It can be seen that as the pH gradually increases, the appearance of the sample remains almost unchanged, which indicates that the composition of the present invention has excellent stability under alkaline conditions.

[0224] As can be seen from this example, the pH range in which the composition of the present invention can form a stable microemulsion is 8-13. The composition can maintain the stability of the microemulsion under alkaline conditions, but will react rapidly under acidic conditions and the microemulsion will become unstable.

[0225] Example 3

[0226] Prepare the samples according to the following method and the amounts in Table 3.

[0227] (1) Aqueous phase: Add 1 g of glycerol to 9 g of deionized water to prepare a glycerol aqueous solution, and then add 0.051 g of phenoxyethanol as a preservative;

[0228] (2) Oil phase: Weigh 0.03 g of Surfactin into a beaker, add glycerol, 0.018 g of squalane, 1,3-butylene glycol, 0.0135 g of isostearic acid, 0.0135 g of isostearyl alcohol, and 0.015 g of deionized water, and stir evenly;

[0229] (3) Add the oil phase to the water phase and stir until uniform.

[0230] Table 3

[0231]

[0232] *Based on the mass percentage of the total mass of the oil phase in the sample except 1,3-butanediol

[0233] The appearance of the samples configured as shown in Figure 5A Figure 5A It can be seen that, in the case of specific glycerol and 1,3-butanediol content, the samples can form microemulsions with good transparency.

[0234] The latex particle size and PDI of the samples were determined by dynamic light scattering, and the results are shown in Figure 5B

[0235] The ternary diagram of glycerol, 1,3-butanediol and other components was drawn, and the component content of the sample forming the microemulsion was marked in the diagram, and the pseudo-ternary phase diagram of the system was drawn according to the range of forming the microemulsion, as shown in Figure 5C

[0236] Therefore, it can be seen that the composition of the present embodiment can form a microemulsion in the range enclosed by the following coordinates of the ternary diagram connected by straight lines:

[0237] (9.85 0.07,90.07),(9.86,0.04,90.11),(9.95,0.07,89.97),(9.96,0.04,90.01),(10.05 0.15,89.81),(10.06,0.04,89.91),(10.24,0.15,89.61),(10.26,0.02,89.72),(10.47,1.71,87.82),(10.65,0.01,89.34).

[0238] Therefore, it can be seen that 1,3-butanediol is an essential substance for forming a microemulsion, and glycerol in the oil phase is not an essential substance, and a microemulsion can also be formed without glycerol in the oil phase.

[0239] Industrial applicability

[0240] The cosmetic composition provided by the present application can be prepared in industry.​​​

Claims

1. A cosmetic composition, characterized by, The composition comprises the following components: (A) isostearic acid, (B) isostearyl alcohol, and (C) other components, which comprise, based on the total weight of the (C) other components: (C1) metal salt of a subtilisin lipopeptide 0.294 wt. %, (C2) squalane 0.176 wt. %, (C3) glycerin 10.666 wt. %, (C4) 1,3-butanediol 0.147 wt. %, (C5) preservative 0.499 wt % and (C6) water 88.218 wt %; wherein the content of the components (A), (B), (C) is within the range enclosed by the following coordinates of an equilateral triangle coordinate system in a ternary diagram of components (A), (B) and (C) connected by straight lines: (0.08,0.13,99.79),(0.06,0.20,99.75),(0.06,0.29,99.65),(0.10,0.29,99.61),(0.15,0.20,99.66),(0.18,0.13,99.69)； wherein the pH range of the cosmetic composition is 8-13.

2. The cosmetic composition according to claim 1, characterized by The (C5) is phenoxyethanol.

3. A cosmetic composition characterized in that, The composition comprises the following components: (a) glycerin (b) 1,3-butanediol 0.01-1.71 wt. % (c) other components, which comprise, based on the total weight of the (c) other components: (c1) metal salt of a subtilisin lipopeptide 0.3282 wt. %, (c2) squalane 0.1969 wt. %, (c3) isostearyl alcohol 0.1477 wt. %, (c4) isostearic acid 0.1477 wt. %, (c5) preservative 0.5579 wt % and (c6) water 98.6216 %; wherein the content of the components (a), (b), (c) is within the range enclosed by the following coordinates of an equilateral triangle coordinate system in a ternary diagram of components (a), (b) and (c) connected by straight lines: (9.85 0.07,90.07),(9.86,0.04,90.11),(9.95,0.07,89.97),(9.96,0.04,90.01),(10.05 0.15,89.81),(10.06,0.04,89.91),(10.24,0.15,89.61),(10.26,0.02,89.72),(10.47,1.71,87.82),(10.65,0.01,89.34)； wherein the pH range of the cosmetic composition is 8-13.

4. The cosmetic composition according to claim 3, characterized by The (c5) is phenoxyethanol.

5. The cosmetic composition according to any one of claims 1 to 4, characterized in that, The composition is an oil-in-water emulsified composition.

Images